Optimization of heparin anticoagulation for hemodialysis

Hemodialysis International

Volumn 15, Issue SUPPL. 1, 2011, Pages

  Davenport, Andrew ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hemodiafiltration; Hemodialysis; Heparin; Unfractionated heparin

Indexed keywords

HEPARIN; PLASMA PROTEIN; PLASTIC;

ANTICOAGULATION; ARTICLE; BLEEDING; BOLUS INJECTION; DRUG BINDING; DRUG EFFICACY; DRUG SAFETY; EXTRACORPOREAL CIRCULATION; HEMODIALYSIS; HUMAN; INFUSION; LEUKOCYTE; NEEDLE; PUNCTURE; REACTION OPTIMIZATION; SYSTEMATIC REVIEW;

ANTICOAGULANTS; HEPARIN; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 80054938445     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2011.00601.x     Document Type: Article

References (29)

1. Kishimoto TK, Viswanathan K, Ganguly T, etal. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med. 2008; 358:2457-2467.
2. Davenport A. Anticoagulation options for intermittent haemodialysis. Minerva Urol Nefrol. 2006; 58:171-180.
3. Davenport A. Anticoagulation options for paediatric haemodialysis. Haemodial Int. 2003;7:168-176.
4. De Vos JY, Marzoughi H, Hombrouckx R. Heparinisation in chronic haemodialysis treatment: Bolus injection or continuous homogeneous infusion? EDTNA ERCA J. 2000; 26:20-21.
5. Ouseph R, Brier ME, Ward RA. Improved dialyzer reuse after use of a population pharmacodynamic model to determine heparin doses. Am J Kidney Dis. 2000;35:89-94.
6. Ward J, Shaw K, Davenport A. Patients' perspectives of constant-site (buttonhole) cannulation for haemodialysis access. Nephron Clin Pract. 2010; 116:c123-c127.
7. Thomas A, Chan A, Hunks MB, Zheng J. Providing an in-centre nocturnal hemodialysis program: The pearls and pitfalls. CANNT J. 2007; 17:39-41.
8. Davenport A. Anticoagulation for continuous renal replacement therapy. Contrib Nephrol. 2004; 144:228-238.
9. Ouseph R, Ward RA. Anticoagulation for intermittent haemodialysis. Semin Dial. 2000; 13:181-187.
10. Davenport A. Membrane designs and composition for haemodialysis, haemofiltration and haemodialfiltration: Past, present and future. Minerva Urol Nefrol. 2010; 62:29-40.
11. Schmitt GW, Moake JL, Rudy CK, Vicks SL, Hamburger RJ. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related von Willebrand factor during haemodialysis. Am J Med. 1987; 83:411-418.
12. Vernon K, Peasegood J, Riddell A, Davenport A. Dialyzers designed to increase internal filtration do not result in significantly increased platelet activation and thrombin generation? Nephron Clin Pract. 2011; 117:c403-408.
13. Docci D, Turci F, Del Vecchio C, Bilancioni R, Cenciotti L, Pretolani E. Haemodialysis-associated platelet loss: Study of the relative contribution of dialyzer membrane composition and geometry. Int J Artif Organs. 1984; 7:337-340.
14. Lee KB, Kim B, Lee YH, etal. Haemodialysis using heparin-bound Hemophan in patients at risk of bleeding. Nephron Clin Pract. 2004; 97:c5-10.
15. Lavaud S, Paris B, Maheut H, etal. Assessment of the heparin-binding AN69 ST haemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J. 2005; 51:348-351.
16. Davenport A. Pre-dilution or post-dilution fluid replacement for continuous veno-venous haemofiltration; that is the question. Nephron Clin Pract. 2003; 94:c83-c84.
17. Oates T, Pinney J, Davenport A. Haemodiafiltration versus high-flux haemodialysis: Effects on phosphate control and erythropoietin response. Am J Nephrol. 2010; 33:70-75.
18. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G. Impact of membrane choice and blood flow pattern on coagulation and heparin requirement-potential consequences on lipid concentrations. Nephrol Dial Transplant. 1997; 12:2638-2646.
19. Kaplan AA. Continuous arteriovenous hemofiltration - and related therapies. In: Jacobs C, Kjellstrand KE, Koch KM, Winchester JF, eds. Replacement of Renal Function by Dialysis. Boston, MA: Kluwer Academic Publishers. 1996; 390-417.
20. Fritz KW, Messerschmidt W. Regional heparinization in extracorporeal haemodialyses. Dtsch Med Wochenschr. 1967; 92:2061-2065.
21. Frank RD, Müller U, Lanzmich R, Groeger C, Floege J. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant. 2006; 21:1013-1018.
22. Chanard J, Lavaud S, Maheut H, Kazes I, Vitry F, Rieu P. The clinical evaluation of low-dose heparin in haemodialysis: A prospective study using the heparin-coated AN69 ST membrane. Nephrol Dial Transplant. 2008; 23:2003-2009.
23. Agarwal B, Shaw S, Hari MS, Burroughs AK, Davenport A. Continuous renal replacement therapy (CRRT) in patients with liver disease: Is circuit life different? J Hepatol. 2009; 51:504-509.
24. Langley PG, Keays R, Hughes RD, etal. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology. (1991)14:251-256.
25. Hofbauer R, Moser D, Frass M etal. Effect of anticoagulation on blood membrane interactions during hemodialysis. Kidney Int. 1999; 56:1578-1583.
26. Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. Nephrol Dial Transplant. 2009; 2:439-447.
27. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of haemodialysis with citrate dialysate: A prospective controlled study. Clin J Am Soc Nephrol. 2009;4:1459-1464.
28. Langenecker SA, Felfernig M, Werba A Mueller CM, Chiari A, Zimpfer M. Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med. 1994; 22:1774-1781.
29. Davenport A, Will EJ, Davison AM. Comparison of the use of standard heparin and prostacyclin anticoagulation in spontaneous and pump-driven extracorporeal circuits in patients with combined acute renal and hepatic failure. Nephron. 1994; 66:431-437.